Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma.
Sensory neural hearing loss (SNHL) was evaluated in the patients who were treated with concurrent chemoradiation therapy for nasopharyngeal carcinoma. Ten from 48 ears showed persistent SNHL. Radiotherapy techniques, radiation dose to inner ear and post-treatment otitis media were significant predicting factors for SNHL.
Oh
Young-Taek
YT
Department of Radiation Oncology, Ajou University School of Medicine, San 5, Woncheon-Dong, Paldal-Gu, Suwon 442-721, South Korea.
Kim
Chul-Ho
CH
Choi
Jin-Hyuk
JH
Kang
Seung-Hee
SH
Chun
Mison
M
D000328:Adult; D002277:Carcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011446:Prospective Studies; D011832:Radiation Injuries / Q000503:physiopathology*
D002945:Cisplatin